Nasdaq · Healthcare
Immunome Inc. (IMNM)
As-reported financials and recent SEC filings for Immunome Inc., latest fiscal period FY2025. Every figure is pulled straight from the company’s EDGAR filings — no estimates.
Snapshot
Revenue
$6.9M
Net income
$-212.4M
Net margin
—
Diluted EPS
$-2.43
ROE
-33.5%
P/E (TTM)
—
Market cap
—
Debt / equity
—
Income statement (as reported)
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | $6.9M | $9.0M | $14.0M | — | — |
| Gross profit | — | — | — | — | — |
| Operating income | $-224.1M | $-305.8M | $-109.5M | $-36.9M | $-25.2M |
| Net income | $-212.4M | $-293.0M | $-106.8M | $-36.9M | $-24.7M |
| Diluted EPS | $-2.43 | $-5.00 | $-1.79 | $-1.03 | $-0.71 |
Source: company XBRL financial statements on SEC EDGAR.
Recent SEC filings
1442026-07-06
View on EDGAR →1442026-07-02
View on EDGAR →42026-07-02
View on EDGAR →1442026-07-02
View on EDGAR →1442026-06-30
View on EDGAR →1442026-06-30
View on EDGAR →42026-06-29
View on EDGAR →1442026-06-25
View on EDGAR →Largest Healthcare peers
Go deeper on IMNM
Search Immunome Inc.’s filings with cited answers, compare it against peers, build an operating model, and track it in your portfolio — all in one place.
Start freeOr check your whole portfolio free — no account needed.
Data sourced from SEC EDGAR (public domain). Figures are as-reported and may be unaudited or restated; verify against the source filing before relying on them. Informational only — not investment advice.